The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors

Background The BRAF.sup.V600E mutation, which accounts for about 60-80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAF.sup.V600E mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is uncle...

Full description

Saved in:
Bibliographic Details
Published in:World journal of surgical oncology 2013-11, Vol.11 (1), p.291-291, Article 291
Main Authors: Choi, Sun Yi, Park, HeonSoo, Kang, Myung Koo, Lee, Dong Kun, Lee, Kang Dae, Lee, Hyoung Shin, Kim, Sung Won, Lee, Eun Nam, Hong, Jong Chul
Format: Article
Language:English
Subjects:
Analysis
Development and progression
Gender
Gene mutations
Genetic aspects
Medicine
Metastasis
Mutation
Otolaryngology
Patient outcomes
Risk factors
Studies
Surgery
Thyroid cancer
Thyroid diseases
University colleges
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The BRAF.sup.V600E mutation, which accounts for about 60-80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAF.sup.V600E mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear. Methods We performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the prevalence of the BRAF.sup.V600E mutation. The associations between the BRAF.sup.V600E mutation and clinicopathologic characteristics were analyzed. Results The BRAF.sup.V600E mutation was observed in 72 patients (71.3%). There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAF.sup.V600E mutant group and wild group. Conclusions The BRAF.sup.V600E mutation is not significantly associated with prognostic factors in PTMC. Keywords: BRAF mutation, Papillary thyroid microcarcinoma, Prognosis
ISSN:1477-7819
1477-7819
DOI:10.1186/1477-7819-11-291